危重患儿替加环素群体药代动力学与目标达成概率
该研究纳入20例接受静脉替加环素的儿童,建立二室群体药代动力学模型并行蒙特卡洛模拟,评估不同年龄分层给药方案的目标达成概率。结果显示标准剂量对敏感链球菌所致CAP、cIAI和cSSSI足够,但对敏感肠杆菌目等需加倍剂量,中介肠杆菌目即使增量亦难达标。
要点
- 标准剂量对敏感链球菌所致CAP、cIAI和cSSSI达标。
- 敏感肠杆菌目等所致cIAI需标准剂量加倍。
- 中介肠杆菌目即使超过4.8 mg/kg增量亦不达标。
核心结论
- 当前替加环素推荐剂量对敏感性较低的病原体可能不足。
研究设计与样本
- 纳入20例接受静脉替加环素的儿童,探索一室与二室模型,并行蒙特卡洛模拟评估年龄分层给药方案的目标达成概率。
主要发现
- 含异速缩放和S形成熟函数的二室模型最佳描述替加环素药代动力学。
- 标准剂量对敏感链球菌(折点0.125 mg/L)所致CAP、cIAI和cSSSI达标。
- 对敏感肠杆菌目、葡萄球菌属或肠球菌属(折点0.5 mg/L),标准剂量在CAP达标,cIAI需标准剂量加倍。
- cSSSI青少年需150 mg更高剂量,但毒性担忧需极度谨慎。
- 中介肠杆菌目(折点4 mg/L)即使剂量超过4.8 mg/kg亦未达PK/PD目标。
关键数值与推荐
- 敏感链球菌折点0.125 mg/L时标准剂量对CAP、cIAI、cSSSI达标。
- 敏感肠杆菌目等折点0.5 mg/L时cIAI需标准剂量加倍,cSSSI青少年需150 mg。
- 中介肠杆菌目折点4 mg/L时剂量超过4.8 mg/kg仍未达标。
临床怎么用
- 危重患儿使用替加环素应依据感染病原体敏感性及感染类型调整剂量。
- 对敏感肠杆菌目等所致cIAI考虑标准剂量加倍。
- 中介肠杆菌目感染不宜仅靠增加替加环素剂量达标。
局限性
- 样本量仅20例儿童。
- 18岁以下使用替加环素安全性数据有限。
- 8岁以下儿童给药指南尚未定义。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Tigecycline is not usually recommended for patients under 18 years due to limited safety data and adverse events, and dosing guidelines for children under 8 remain undefined. However, it remains a critical treatment option for life-threatening multidrug-resistant infections in critically ill children. This study aimed to characterize the population pharmacokinetics (PopPK) of tigecycline in children, identify key covariates affecting PK variability and propose optimized dosing regimens tailored to specific infection types. MATERIALS AND METHODS: This study enrolled 20 children receiving intravenous tigecycline. One- and two-compartment models were explored. Monte Carlo simulations with age-stratified tigecycline dosing regimens were performed to evaluate the probability of target attainment (PTA) for various dosing regimens. RESULTS: A two-compartment model incorporating allometric scaling and a sigmoidal maturation function best described tigecycline PK. PTA analyses indicated that the standard dose was sufficient for children with infections caused by susceptible Streptococcus groups (breakpoint 0.125 mg/L) across community-acquired pneumonia (CAP), complicated intra-abdominal infections (cIAI) and complicated skin and skin structure infections (cSSSI). For susceptible Enterobacterales, Staphylococcus spp. or Enterococcus spp. (breakpoint 0.5 mg/L), the standard dose reached PK/pharmacodynamic (PD) targets for CAP, while cIAI required twice the standard dose. cSSSI necessitated higher dosing (150 mg) in adolescents; however, potential toxicity concerns necessitate extreme caution with such escalation. Infections caused by Enterobacteriaceae with intermediate resistance (breakpoint 4 mg/L) failed to achieve PK/PD targets even with increased doses exceeding 4.8 mg/kg. CONCLUSIONS: Overall, these results suggest that current dosing recommendations may be insufficient for less susceptible pathogens.
引用
- Hu W, Yuan Y, Tan B, et al. Population pharmacokinetics and probability of target attainment of tigecycline in critically ill children. J Antimicrob Chemother. 2026. PMID: 42085673. doi:10.1093/jac/dkag156
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。